Business
Cardiol Therapeutics Announces Study Results Presented at the 2023 Annual Meeting of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases
Toronto, Ontario--(Newsfile Corp. - November 16, 2023) - Cardiol Therapeutics Inc. (NASDAQ: CRDL...
About this update from Cardiol Therapeutics Inc. Class A
[{"type":"text","content":"Cardiol Therapeutics Announces Study Results Presented at the 2023 Annual Meeting of the European Society of Cardiology Working Group on Myocardial and Pericardial DiseasesToronto, Ontario--(Newsfile Corp. - November 16, 2023) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (\"Cardiol\" or the \"Company\"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announced today that study results demonstrated an experimental model of pericarditis induces mesothelial to mesenchymal transition (\"MMT\") and that this process is inhibited by cannabidiol treatment, the active pharmaceutical ingredient in CardiolRx™. An abstract summarizing these results was submitted by the Company's international research collaborators from the University of Virginia and Houston Methodist DeBakey Heart & Vascular Center to the 2023 Annual Meeting of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases (\"MPD2023\") held on November 15 and 16, 2023 in Belgrade, Serbia.The poster entitled \"Cannabidiol Inhibits the Mesothelial to Mesenchymal Transition in Experimental Pericarditis\" was presented for general viewing within the poster sessions of the MPD2023 Scientific Programme. The results presented are a continuation of a research collaboration between Cardiol and the University of Virginia, which previously reported at the American Heart Association Scientific Sessions 2022 that cannabidiol reduces pericardial effusion and thickness in the same experimental model of pericarditis. \"We are intrigued by these new findings that further support an anti-fibrotic benefit of CardiolRx™, in addition to its anti-inflammatory properties that were previously reported in this pre-clinical model,\" commented Dr. Andrew Hamer, Cardiol Therapeutics' Chief Medical Officer and Head of Research & Development. \"Fibrosis is the basis of more severe long-term complications of recurrent pericarditis, for which no specific anti-fibrotic therapies are currently available, suggesting a potentially broader therapeutic benefit of CardiolRx™.\"MMT is a complex and stepwise biological process whereby a mesothelial cell, the main cell type lining internal organs and several of the body's int...